We determined clonality of thyroid tumors from female patients who had restriction fragment length polymorphisms (RFLP) in the X chromosome genes hypoxanthine phosphoribosyltransferase (HPRT) or phosphoglycerate kinase (PGK). We screened normal thyroid tissue from 59 female patients; of the informative cases 14 were heterozygous for a Bgl I site on PGK and 4 were heterozygous for a Bam HI site on HPRT. In monoclonal tumors, one of the polymorphic alleles was selectively digested after additional digestion with Hpa II, a methylation sensitive enzyme, whereas in polyclonal tissue both were decreased to a similar extent. Normal thyroid tissue from all patients showed a polyclonal pattern. Of the 18 tumors studied, 12 were solitary thyroid nodules, and 6 were obtained from multinodular goiters (MNG). The following were monoclonal: 6/6 follicular adenomas, 2/2 follicular carcinomas, and 1/1 anaplastic carcinoma. Two of the three papillary carcinomas showed intermediate patterns, possibly due to contaminating effects of stromal tissue present in most of these neoplasms. Of the six nodules from MNG, four were polyclonal. The two largest gave a distinct monoclonal pattern. Most solitary thyroid tumors are monoclonal, supporting a somatic cell mutation model of thyroid neoplasm formation. Nodules from MNG are largely hyperplastic, although monoclonal neoplasms do occasionally arise within these glands. The specific somatic mutations leading to clonal expansion and determination of tumor phenotype are presently unknown. (J. Clin. Invest. 1990. 86:120-125.) Key words: follicular neoplasm * papillary carcinoma * multinodular goiter * X chromosome inactivationphosphoglycerate kinase * hypoxanthine phosphoribosyltransferase Introduction
neoplastic, and in the case of neoplasms, to differentiate a follicular adenoma from a carcinoma. There have been several studies documenting discrepancies between observers in the pathological diagnosis of thyroid tumors, which are reported to occur in up to 24% of cases (2, 3) . These difficulties stem from major gaps in our knowledge of the biology of thyroid neoplasms.
Understanding the origin of neoplasia may be advanced by studying the clonal composition of tumor cell populations. Since thyroid neoplasms are a heterogeneous group of disorders that differ in their histopathological and clinical characteristics, determining their clonal composition will provide valuable information for future studies into their pathogenesis. If tumors arise from a single cell, a somatic cell mutation model of thyroid neoplasm formation will be likely (4) . Conversely, the existence of polyclonal tumors will suggest that extrinsic growth-promoting factors (i.e., TSH or other growth factors) may play a determining role in tumor formation.
Determination of clonality can be achieved by X chromosome inactivation analysis. This methodology takes advantage of the fact that, according to the Lyon hypothesis (5) , one of the two X chromosomes in all female somatic cells is functionally inactivated early in mammalian embryogenesis. X-inactivation is a random process in which either the maternally or paternally derived X can be inactivated; once established, however, X-inactivation is fixed for a given cell and its progeny (6) . Normal polyclonal female tissue is a mosaic consisting ofa roughly equal mixture of two types of cells, some ofwhich contain an active maternal X chromosome, while others possess active paternal X chromosomes. In the past, clonal analyses have been performed by examining the protein polymorphism exhibited by glucose 6 phosphate dehydrogenase (G6PD)' (7, 8) , a protein coded for in the X chromosome. This strategy has the drawback that G6PD polymorphism is only observed in a small proportion of black females (9) . Furthermore, false results can be obtained if the tumor cell type expresses the gene at a different rate than the surrounding mesenchymal cells. Since somatic cells contain the same amounts of DNA, these problems are avoided by using markers present in X chromosome genes. Recently, restriction fragment length polymorphisms (RFLPs) have been identified that can distinguish the maternal and paternal copies of certain X chromosome genes from one another (10) . Furthermore, there is evidence that changes in the expression of many genes, including those in the X chromosome, are accompanied by changes in the methylation of cytosine residues (1 1). Methylation differences can be identified by certain restriction endonucleases that will differentially digest DNA according to whether or not 1. Abbreviations used in this paper: ACR, allelic cleavage ratio; G6PD, glucose 6-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyltransferase; MNG, multinodular goiter; PGK, phosphoglycerate kinase; RFLP, restriction fragment length polymorphism. their recognition sequences contain methylated cytosine residues.
Combined DNA digestion with a methylation-specific enzyme and the restriction enzyme giving rise to an RFLP determines whether a population of tumor cells or tissue is monoclonal or polyclonal (12, 13) . With this approach, using RFLPs in the X chromosome genes hypoxanthine phosphoribosyltransferase (HPRT) and phosphoglycerate kinase (PGK), the clonal origin of a variety of human benign and malignant neoplasms has been determined (14) . Arnold et al. have utilized this technique to undertake the clonal analysis of human parathyroid adenomas (15) . They found it useful in distinguishing parathyroid adenomas (which showed a monoclonal pattern) from parathyroid hyperplasia (polyclonal pattern).
As will be detailed in this report, we found using HPRT and PGK gene polymorphisms as markers that most solitary benign and malignant thyroid tumors do indeed appear to be monoclonal. Although most nodules from multinodular goiters were polyclonal, large tumors arising within these glands occasionally showed monoclonal patterns, suggesting that somatic cell transformation can give rise to true neoplasms in these predominantly hyperplastic goiters.
Methods
Thyroid tumor collection. Thyroid nodules from female patients were obtained at surgery and immediately frozen in liquid nitrogen. Attending pathologists were requested to provide tumor samples from within the capsule to prevent contamination with normal thyroid tissue. Whenever possible, normal thyroid tissue from the same individual was collected separately. In patients with multinodular goiters (MNG), samples were taken from the largest available tumor, and lymphocyte preparations from peripheral blood were used as a source of normal polyclonal tissue.
Rationalefor X chromosome inactivation analysis (12) (13) (14) . To determine clonality oftumors by this strategy requires two conditions: (a) a method of distinguishing the two X chromosome alleles from each other, and b) the ability to tell which X chromosome(s) are active in a given cell population. To distinguish the paternal from the maternal alleles, we identified female patients with heterozygous polymorphisms in either the X chromosome gene PGK and/or HPRT. In the PGK gene there is a polymorphic Bgl I site. 33% of females are heterozygous for this site. After Eco RI-Bgl II digestion, subsequent digestion with Bgl I will reveal bands of 1.7 These polymorphisms are in the vicinity of methylation sites, which differ in their methylation status according to whether the gene is active or inactive. We determined the methylation status of each of the polymorphic alleles by additional digestion with the methylation sensitive enzyme Hpa II. The HPRT gene has two Hpa II sites that are methylated in all inactive X chromosomes, whereas one or the other of these is unmethylated in active X chromosomes. Hpa II digestion of Bam HI/Pvu II digested DNA of a heterozygous female will be expected to show reduced intensity of both the 18-and the 12-kb fragments ifthe tumor tissue is polyclonal. Ifthe tumor is monoclonal, the 18-and 12-kb alleles will not be digested equivalently by Hpa II, and one of them, the inactive allele, will disappear completely. Exceptionally, Hpa II sites 2-9 may be methylated in the inactive allele (type II alleles), and therefore even monoclonal neoplasms will show resistance to Hpa II digestion of both the 18-and 12-kb fragments using the HPRT-800 probe (14) . We encountered two such examples in our series, which were considered noninformative. In the PGK studies, Hpa II digestion of Eco RI-Bgl II/Bgl I-digested tumor DNA probed with the PGK clone will be expected to show 60-75% reduction in the intensity ofboth the 1.7-and 1.3-kb alleles ifthe tumor is polyclonal. If the tumor is monoclonal, one allele will be selectively decreased by Hpa II digestion. Exceptionally, monoclonal tumors may have both alleles completely digested away with Hpa II (14) . We found one such case, which was considered noninformative. The PGK probe has been reported to cross-hybridize to a PGK-related Eco RI-Bgl II fragment of -1.7 kb (14) . With the stringency conditions used in our study we did not encounter this problem, as evidenced by consistently obtaining complete Hpa II cleavage of control male DNA containing a 1.7-kb PGK allele. DNA extraction. DNA was extracted from tissues and lymphocytes by ultracentrifugation through a cesium chloride gradient (16) . Briefly, thyroid tissue was ground under liquid N2 using mortar and pestle. The DNA layer was recovered after ultracentrifugation through a 2.4-M and 5.7-M CsCl cushion and precipitated in 2.5 vol of ethanol. The DNA was recovered by spooling, rinsed in 10 ml of 80% ethanol, and digested at 370C for 48 h with 1 stg/ml proteinase K in a buffer containing 150 mM NaCl, 10 mM Tris, pH 7.5, 10 mM EDTA and 0.4% SDS. The 
Results
We screened normal tissue DNA from 59 female patients undergoing thyroid surgery for the presence of heterozygous polymorphisms in the HPRT and/or the PGK genes. Individuals heterozygous for the respective polymorphic sites revealed the presence of two bands upon digestion with the appropriate restriction enzymes. Normal thyroid tissue from all informative cases showed a polyclonal pattern upon further digestion with Hpa II, and their tumors could thus be subjected to clonal analysis. 18 (19) . After inducing thyroid tumors with a variety of goitrogens, they observed that lesions identified histologically as adenomas (encapsulated, monomorphous and hypercellular) were consistently monoclonal by enzyme histochemistry. Nodules, defined as circumscribed tumors with prominent stroma and areas of normal follicular architecture, were largely polyclonal.
14 years ago, Fialkow et al. (7) (8) (9) used protein electrophoresis to differentiate the A or B isozymes ofG6PD in heterozygous women in order to perform clonality studies of human tumors. Among them, he studied four follicular adenomas and five thyroid carcinomas, and found them all to be monoclonal (20) . Arnold et al. established the clonal characteristics of human parathyroid adenomas using X-chromosome gene RFLPs, which they found to be largely monoclonal (15) . In this paper we have validated this latter strategy to study the clonal composition of benign and malignant thyroid neoplasms. As expected, normal thyroid tissue invariably showed a polyclonal pattern, indicating that the X-inactivation process occurs at a point in thyroid ontogeny when the gland is already multicellular, and that normal follicular cells consist of a rela- tively even population of thyrocytes with active maternal and paternal X chromosome alleles. All the solitary follicular nodules we examined (six adenomas and three carcinomas) gave clear cut monoclonal patterns. We also studied three papillary carcinomas, two of which unexpectedly showed polyclonal patterns.
Several potential caveats must be discussed in the interpretation of these data. In particular, possible causes of inappropriate assignment of clonality must be considered. Firstly, improperly dissected tumor tissue may contain substantial amounts of stromal cells. As the "contaminating" nontumoral tissue will be polyclonal, the RFLP-methylation pattern will be shifted towards that observed in the patient's normal polyclonal tissues. To minimize this problem, extreme care was taken to obtain tissue from within the capsule of the nodules. In the case of the papillary carcinomas, however, a substantial amount of stromal tissue was interspersed with the neoplastic cells, which complicates the interpretation of the clonal analysis. It is also possible that some neoplasms could have unusual methylation patterns of any of the two genes, as has been reported for neuroblastomas (14) . Vogelstein et al. did not encounter this phenomenon in a large variety of neoplasms (14) . Other factors, such as aging, have been reported to be associated with reactivation of some inactive X chromosome alleles, and could conceivably lead to false polyclonal patterns. However, reactivation of the HPRT locus with aging does not appear to occur to any significant extent (21).
In all likelihood, papillary carcinomas arise due to somatic cell mutations. We have recently reported the presence of a marked amplification of a truncated H-ras allele, which also contained an activating point mutation in an aggressive papillary carcinoma (22) . Fusco et al. used the NIH3T3 cell focus assay to isolate transforming DNA from papillary carcinoma tissue (23) . Recently, these investigators reported that the papillary carcinoma transforming gene resulted from the fusion of the tyrosine kinase domain of the ret protooncogene to an unknown amino-terminal sequence (24) . These observations therefore indicate that these tumors have clonal characteristics, and that the polyclonal pattern found in two of the three papillary carcinomas we tested may have been artefactual. It should be noted, however, that there is histological evidence that some papillary carcinomas are either multicentric, or that they give rise to intrathyroidal micrometastasis early in the neoplastic process. It is therefore theoretically possible that a mutational event occurring independently in two or more different sites within the thyroid may have given rise to a polyclonal neoplasm sharing an identical somatic cell genetic lesion.
Studer et al. have suggested that most thyroid nodules from nodular goiters are polyclonal, based on the observation that within thyroid tissues there is considerable between-cell and between-follicle variability in functional processes such as thyroglobulin synthesis, iodination and peroxidase content, as well as in growth potential (25) (26) (27) (28) (29) . Under the influence of goitrogenic stimuli, follicular cells tend to maintain their inherent phenotypic characteristics, including their growth responsiveness, which appears to be transmitted to the progeny of the individual cells (26) , and explains the nodular growth pattern observed in these glands. Our data showing that tumors from nodular goiters are mostly polyclonal by X chromosome inactivation analysis is therefore compatible with this model. Two of the six tumors obtained from nodular goiters, however, had distinct monoclonal patterns, indicating that true adenomas may occur in these otherwise hyperplastic glands. No inferences on the frequency of adenoma formation in nodular goiters can be made, since many patients with this condition are sent to surgery because they harbor a large "dominant" nodule, and the samples we gathered are likely to be biased by this fact. Indeed, the two monoclonal tumors were the largest of all those obtained from nodular thyroids in which we could perform clonal analysis. We recently observed that 4 of 19 tumors from nodular goiters contained point mutations of ras oncogenes (29) . Interestingly, none of the polyclonal nodules had ras mutations, whereas one of the two monoclonal tumors had a point mutation in codon 12 of H-ras.
We have therefore demonstrated that most solitary nodules occurring in otherwise normal thyroid glands are monoclonal neoplasms. Conversely, tumors from nodular thyroid tissue are largely polyclonal, and are probably hyperplastic responses to goitrogenic stimuli. Within the hyperplastic glands, true adenomas may occasionally arise through one or more somatic cell mutations, which may confer these neoplasms with a growth advantage. Defining the sequence of somatic cell mutations which determine the various thyroid tumor phenotypes is of critical importance to understand the biology of these frequent neoplasms.
